Shares of Cogent Biosciences (COGT) fell about 6% after the company submitted a New Drug Application (NDA) to the FDA for bezuclastinib in patients with gastrointestinal stromal tumors (GIST). NDA submission is a material regulatory milestone that advances the commercialization pathway but is not an approval; the article provides no timing or trial-readout details. The roughly 6% decline reflects a negative near-term market reaction despite the regulatory progress.
Shares of Cogent Biosciences (COGT) fell about 6% after the company submitted a New Drug Application (NDA) to the FDA for bezuclastinib in patients with gastrointestinal stromal tumors (GIST). NDA submission is a material regulatory milestone that advances the commercialization pathway but is not an approval; the article provides no timing or trial-readout details. The roughly 6% decline reflects a negative near-term market reaction despite the regulatory progress.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
